• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Latinos and chronic hepatitis C: a singular population.

作者信息

Rodríguez-Torres Maribel

机构信息

Fundación de Investigación de Diego, Santurce, Puerto Rico.

出版信息

Clin Gastroenterol Hepatol. 2008 May;6(5):484-90. doi: 10.1016/j.cgh.2008.02.036.

DOI:10.1016/j.cgh.2008.02.036
PMID:18455693
Abstract

Latinos are the largest minority in the USA and have higher rates of HCV infection. The course of chronic hepatitis C in Latinos is more aggressive, with higher risk to develop cirrhosis than any other ethnic group or race. Available information suggests that more rapid progression of liver disease is aggravated by decreased efficacy to treatment with available therapies. The causes for more aggressive progression and decreased efficacy of treatment are complex. Factors related to metabolic syndrome, insulin resistance, and hepatic steatosis are important, as well as genetic differences, not only for metabolic syndrome but for immune responses to interferon. In addition, there are substantial barriers for Latinos to access medical care. Language, cultural differences, and socioeconomic factors, including lack of medical insurance, more frequent use of alcohol, and possible medical care provider bias, are significant obstacles to diagnosis and treatment. The severity of the liver disease and the association to metabolic syndrome medical conditions justify that Latinos be considered a special population with urgent need of intervention strategies. In this article we present all the available evidence on epidemiology, natural history of chronic hepatitis C, and efficacy of anti-HCV therapy in Latinos infected with HCV.

摘要

相似文献

1
Latinos and chronic hepatitis C: a singular population.
Clin Gastroenterol Hepatol. 2008 May;6(5):484-90. doi: 10.1016/j.cgh.2008.02.036.
2
Impact of obesity on treatment of chronic hepatitis C.肥胖对慢性丙型肝炎治疗的影响。
Hepatology. 2006 Jun;43(6):1177-86. doi: 10.1002/hep.21239.
3
"Maintenance" treatment for patients with cirrhosis related to hepatitis C.丙型肝炎相关肝硬化患者的“维持”治疗。
Clin Gastroenterol Hepatol. 2007 Apr;5(4):427-9. doi: 10.1016/j.cgh.2007.02.005.
4
Chronic hepatitis C in the Hispanic/Latino population living in the United States: a literature review.美国西班牙裔/拉丁裔人群中的慢性丙型肝炎:文献综述
Gastroenterol Nurs. 2008 Jan-Feb;31(1):17-25; quiz 26-7. doi: 10.1097/01.SGA.0000310931.64854.5f.
5
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.不断变化的患者群体中慢性丙型肝炎感染治疗的成本效益
JAMA. 2003 Jul 9;290(2):228-37. doi: 10.1001/jama.290.2.228.
6
Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated.丙型肝炎且肝功能酶正常:治疗还是不治疗。正方观点:大多数患者应接受治疗。
Am J Gastroenterol. 2004 Jun;99(6):972-3. doi: 10.1111/j.1572-0241.2004.40510.x.
7
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management.人类免疫缺陷病毒与丙型肝炎病毒合并感染:流行病学、自然史、治疗选择及临床管理
Infection. 2004 Feb;32(1):33-46. doi: 10.1007/s15010-004-3063-7.
8
Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.脂肪肝及相关因素对慢性丙型肝炎患者联合抗病毒治疗疗效的影响
Liver Int. 2006 Mar;26(2):166-72. doi: 10.1111/j.1478-3231.2005.01219.x.
9
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.肝铁蓄积与慢性丙型肝炎的疾病进展及对干扰素/利巴韦林联合治疗的耐药性相关。
J Gastroenterol Hepatol. 2007 Nov;22(11):1886-93. doi: 10.1111/j.1440-1746.2006.04759.x.
10
Advances in the treatment of hepatitis C.丙型肝炎治疗的进展。
Adv Intern Med. 2000;45:65-105.

引用本文的文献

1
Racial and Ethnic differences in Chronic Hepatitis C Infection Prevalence and Mortality Among Inpatients with Coronary Artery Disease in the United States, 2016 to 2021.2016年至2021年美国冠心病住院患者慢性丙型肝炎感染患病率和死亡率的种族和民族差异
J Racial Ethn Health Disparities. 2025 Jun 23. doi: 10.1007/s40615-025-02520-8.
2
Screening for Hepatitis C Among Community Health Center Patients by Ethnicity and Language Preference.按种族和语言偏好对社区卫生中心患者进行丙型肝炎筛查。
AJPM Focus. 2023 Feb 4;2(2):100077. doi: 10.1016/j.focus.2023.100077. eCollection 2023 Jun.
3
Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.
解析酒精使用和丙型肝炎对拉丁裔个体胰岛素作用的影响。
Alcohol Clin Exp Res. 2022 Jan;46(1):87-99. doi: 10.1111/acer.14743. Epub 2021 Nov 23.
4
Impact of Moderate Alcohol Discontinuation on Insulin Action and Secretion in Latinos With and Without Hepatitis C.中美洲和拉丁美洲人群中,适度戒酒对胰岛素作用和分泌的影响:伴有或不伴有丙型肝炎病毒感染。
Alcohol Clin Exp Res. 2018 Mar;42(3):492-499. doi: 10.1111/acer.13576. Epub 2018 Feb 1.
5
Natural History of Hepatitis C.丙型肝炎的自然史
Gastroenterol Clin North Am. 2015 Dec;44(4):717-34. doi: 10.1016/j.gtc.2015.07.003. Epub 2015 Aug 25.
6
Hepatitis C Infection Among Hispanics in California.加利福尼亚州西班牙裔人群中的丙型肝炎感染情况
J Addict Dis. 2015;34(4):263-73. doi: 10.1080/10550887.2015.1074500.
7
Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection.肝脏炎症是有糖尿病前期风险的拉丁裔人群患糖尿病前期的一个风险因素,无论其是否感染丙型肝炎。
Liver Int. 2015 Jan;35(1):101-7. doi: 10.1111/liv.12676. Epub 2014 Sep 20.
8
Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley.加利福尼亚中部谷区健康献血者中乙型肝炎和丙型肝炎感染的血清流行率。
Gut Liver. 2013 Jan;7(1):66-73. doi: 10.5009/gnl.2013.7.1.66. Epub 2012 Dec 14.
9
Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.2009-2010 年美国少数族裔人群中的丙型肝炎检测、感染及与医疗保健的关联
Am J Public Health. 2013 Jan;103(1):112-9. doi: 10.2105/AJPH.2012.300858. Epub 2012 Nov 15.
10
Predicting the probable outcome of treatment in HCV patients.预测 HCV 患者治疗的可能结果。
Therap Adv Gastroenterol. 2009 Sep;2(5):287-302. doi: 10.1177/1756283X09339079.